Chassis Strain Selection & Benchmarking: EcN vs Lactococcus vs Bifidobacterium

Q: What in vivo models do you recommend transitioning to after in vitro benchmarking?

Once the optimal chassis is selected via in vitro testing, we typically transition to targeted murine models. Depending on the indication, this could involve DSS-induced colitis models for inflammatory bowel disease, specific solid tumor models for oncology applications, or colonization-tracking studies utilizing in vivo imaging systems (IVIS).

The Bottleneck of Chassis Selection

Developers of engineered live biotherapeutic products (eLBPs) face a critical, early-stage dilemma: selecting the right microbial chassis. An incorrect choice often leads to quantifiable failure modes during preclinical development:

Insufficient Yield: ELISA or functional activity readouts fall short due to poor secretion mechanisms or intracellular degradation.
Failure to Reach or Persist: The chassis is rapidly cleared by gastric acid (SGF) and bile salts (SIF), or fails to exhibit effective mucosal adhesion.
Loss of Engineered Elements: Plasmids drop off rapidly during antibiotic-free continuous culturing or in vivo passage.

While Escherichia coli Nissle 1917 (EcN), Lactococcus lactis, and Bifidobacterium species are the industry standards, avoiding these pitfalls requires moving beyond theoretical comparisons. You need empirical, side-by-side benchmarking tailored to your specific payload and target microenvironment.

Comprehensive Chassis Benchmarking Services

Our systematic benchmarking platform actively evaluates your therapeutic gene across multiple candidate chassis. By standardizing the testing environment, we eliminate variables and provide true comparative data.

Therapeutic Protein Expression Profiling

We engineer each candidate chassis to express your target peptide or protein. Utilizing precision ELISA, Western blotting, and functional activity assays, we quantify both intracellular accumulation and secretory efficiency across candidates, establishing a reliable baseline of therapeutic output.

Genetic Stability Assessment

A live biotherapeutic is only effective if it retains its engineered elements. We perform rigorous generational passaging without antibiotic selection pressure, utilizing qPCR and sequencing to monitor plasmid loss rates and chromosomal integration stability over time.

Acid and Bile Salt Tolerance

In vivo survival is paramount. We subject each chassis to simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) models. By tracking viability (CFU/mL) across pH gradients and varying bile salt concentrations, we map the physiological robustness of each strain.

Adhesion & Persistence Potential

Utilizing in vitro cell models (e.g., Caco-2, HT-29) and ex vivo mucosal models, we benchmark the ability of EcN, Lactococcus, and Bifidobacterium to adhere to the host epithelium. These in vitro and ex vivo metrics serve as robust predictors of localized delivery potential, guiding definitive in vivo colonization studies.

Benchmarking Criteria	Escherichia coli Nissle 1917 (EcN)	Lactococcus lactis	Bifidobacterium spp.
Gram Status & Physiology	Gram-negative, Facultative anaerobe	Gram-positive, Facultative anaerobe	Gram-positive, Strict anaerobe
Protein Expression Systems	Highly developed, versatile promoters, excellent for complex/large proteins.	Well-established NICE system, excellent for secreted mucosal proteins.	Developing tools; excellent for localized tumor targeting.
GI Survival Profile	High tolerance to bile; transient colonization.	Moderate tolerance; requires protective formulation.	Moderate to high tolerance; native colonic colonizer.
Best-Fit Indications	Solid tumors, localized GI inflammation, infections.	Mucosal vaccines, IBD, upper GI peptide delivery.	Colorectal cancer, lower GI metabolic & immune modulation.
Common Engineering Moves	Secretion pathways (e.g., hemolysin), biocontainment (kill switches).	NICE system optimization, encapsulation strategies.	Chromosomal integration, hypoxia-driven tumor-targeting promoters.
Safety Profile	Widely used, but bears LPS (potential immunogenicity).	GRAS status, food-grade, no LPS.	GRAS status, key component of healthy infant microbiome.

What You Receive: Actionable Deliverables

We do not just hand over raw data. At the conclusion of our benchmarking program, you receive a comprehensive strategy package designed to accelerate your IND-enabling studies.

Chassis Recommendation Matrix

A quantified scoring matrix ranking each strain across expression, viability, and stability parameters specific to your payload.
Trade-off Rationale

Detailed scientific explanations detailing why one chassis outperforms another in your specific disease model context.
Next-Step Engineering Proposals

Customized plans for optimization, such as integrating biocontainment systems, fine-tuning promoter strength, or advancing to in vivo efficacy trials.

"The recommendation matrix provided unparalleled clarity, allowing us to pivot from our initial assumed chassis to a far more stable alternative prior to animal studies."

Our Benchmarking Workflow

1

Project Scoping

Define therapeutic payload, target site, and selection criteria.

2

Strain Engineering

Transformation of payload into EcN, Lactococcus, and Bifidobacterium.

3

Parallel Benchmarking

Executing expression, stability, and in vitro tolerance assays simultaneously.

4

Data Synthesis

Compilation of metrics into the Recommendation Matrix.

Published Data: Gastrointestinal Challenges in Live Biotherapeutic Delivery

Our benchmarking protocols are rooted in established microbiological research and physiological realities. Understanding the host environment is critical for accurate in vitro to in vivo translation.

Recent literature rigorously details the harsh physiological barriers engineered bacteria must overcome to function as therapeutics. According to Wang et al. (2025), administering engineered probiotics orally introduces them to a gauntlet of stressors, including extreme pH fluctuations, digestive enzymes, and bile acids in the upper gastrointestinal tract.

Upon reaching the target site (often the intestines or colon), the chassis must then compete with the dense, native microbiome and penetrate the mucosal layer to establish colonization and deliver the therapeutic molecule effectively. The choice of chassis heavily dictates survival through these stages. For instance, Gram-positive Lactococcus lactis may require different encapsulation strategies compared to the robust, Gram-negative EcN, while anaerobic Bifidobacterium possess natural advantages for colonic persistence.

Key gastrointestinal factors influencing microbial chassis survival and colonization. (Creative Biolabs Authorized) — Fig.1 Key gastrointestinal parameters affecting chassis survival and colonization. ^2,3

Recommended Live Biotherapeutic Services

Beyond initial strain selection and benchmarking, Creative Biolabs offers an end-to-end suite of services to drive your live biotherapeutic program from concept to clinical readiness. Explore our specialized solutions designed to seamlessly integrate with your chosen chassis.

Frequently Asked Questions

Our selection begins with an analysis of your therapeutic protein's complexity, desired secretion pathways, and target microenvironment. EcN generally provides higher yields for complex proteins and naturally navigates the gut effectively, but its Gram-negative status means it contains LPS. L. lactis lacks LPS, offering a safer food-grade profile, and excels in secreting smaller peptides, though it may require encapsulation for gastric survival. Our benchmarking quantifies these trade-offs specific to your payload.

Yes. We frequently integrate client-developed proprietary strains into our benchmarking matrix, evaluating them side-by-side against standard controls like EcN or Bifidobacterium longum under identical in vitro conditions to validate competitive advantages.

We utilize continuous culturing techniques spanning 50-100 generations without antibiotic selection pressure. Throughout this process, we employ qPCR, colony forming unit (CFU) plating on selective/non-selective media, and targeted sequencing to determine the precise rate of plasmid loss or chromosomal mutation.

Once the optimal chassis is selected via in vitro testing, we typically transition to targeted murine models. Depending on the indication, this could involve DSS-induced colitis models for inflammatory bowel disease, specific solid tumor models for oncology applications, or colonization-tracking studies utilizing in vivo imaging systems (IVIS).

Other Resources

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic Strain Products for NGP Research - Brochure

Custom Small-scale Probiotic Production - Brochure

Live Biotherapeutics - Creative Biolabs - Video

References

Xiang, Xiong, et al. "Recent advances of engineered bacteria for therapeutic applications." Molecular Therapy (2025). https://doi.org/10.1016/j.ymthe.2025.11.013
Wang, Xiaohua, et al. "Engineered probiotics for inflammatory bowel disease therapy: mechanisms, delivery strategies, and precision medicine." Frontiers in Microbiology 16 (2025): 1696524. https://doi.org/10.3389/fmicb.2025.1696524
Distributed under Open Access license CC BY 4.0, without modification.